

IN THE CLAIMS:

Please substitute currently amended claim numbers 4-10, 27 and 29 for the pending claims having the same claim numbers.

Please cancel claims 1 and 11-25 without prejudice or disclaimer.

1. (canceled)
2. (previously presented) A pharmaceutical composition for treating a hepatic disorder and/or for increasing the number of immune cells and platelets in a patient consisting essentially of a therapeutically effective amount of a buffered aqueous extract of Anemone hepatica and Nigella sativa, and a pharmaceutically acceptable carrier, wherein the extract of Nigella sativa is present in a concentration of not less than 20% weight per volume.
3. (canceled)
4. (currently amended) A composition according to claim 1 ± 2, wherein the composition is in a form of a tablet or capsule.
5. (currently amended) A composition according to claim 1 ± 2, wherein the composition is in a form of a liquid or suspension.
6. (currently amended) A composition according to claim 1 ± 2, wherein the composition is in a form of a sterile preparation for intra-muscular, subcutaneous, or intra-venous injection.
7. (currently amended) A composition according to claim 1 ± 2, wherein the composition is in a form of nasal spray.

8. (currently amended) A composition according to claim 1 2, wherein the composition is in a form of a topical application.
9. (currently amended) A composition according to claim 1 2, wherein the composition is in a form of a transdermal system.
10. (currently amended) A composition according to claim 1 2, wherein the composition is in a form of suppository.

Claims 11-25 (canceled)

26. (canceled)

27. (currently amended) The pharmaceutical composition of ~~either one of claims 1, or claim~~ 2, wherein the composition is effective for treating patients suffering from a hepatic disorder selected from the group consisting of chronic hepatitis, advanced/late stage hepatitis, hepatitis caused by hepatitis virus genotypes I, II, III or IV, a hepatic disorder characterized by fibrosis and/or cirrhosis, a hepatic disorder resulting from an autoimmune disease and a hepatic disorder resulting from a drug treatment.
28. (previously presented) The composition of claim 27, wherein the patients suffering from said hepatic disorder exhibit advanced stage liver disease characterized by fibrosis and cirrhosis, and wherein treating with said composition results in modifying disease activity, including but not limited to, a decrease in hepatitis viral load, and a decrease in liver enzymes alanine aminotransferase (ALT) levels and aspartate aminotransferase (AST) levels.
29. (currently amended) The composition of ~~either one of claims 1 or claim~~ 2, wherein said composition is effective in treating the cirrhosis and fibrosis associated with an advanced/late stage hepatic disorder.